
Emend (aprepitant) is owned by Merck & Co. (NYSE: MRK), a publicly traded American pharmaceutical company headquartered in Rahway, New Jersey. The FDA approved Emend in 2003 for preventing chemotherapy-induced nausea and vomiting. U.S. generic entry began in 2019 following patent expiration. Merck generated $16.2 billion in revenue in 2025, driven primarily by Keytruda. Emend remains available as a branded product alongside generic aprepitant.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Emend | Merck & Co. | Wholly owned |
Aprepitant was developed by Merck & Co. through research into substance P and its receptor, the neurokinin-1 (NK-1) receptor. Substance P is a neuropeptide that plays a key role in the vomiting reflex. By blocking the NK-1 receptor, aprepitant prevents substance P from triggering nausea and vomiting signals in the brain.
The FDA approved Emend on March 26, 2003, for use in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy, including high-dose cisplatin. The approval was based on clinical trials demonstrating that adding Emend to a standard regimen of a 5-HT3 receptor antagonist (like ondansetron) and a corticosteroid (like dexamethasone) significantly improved CINV control.
In 2005, the FDA approved Emend for use with moderately emetogenic chemotherapy as well. The IV formulation, fosaprepitant (Emend for Injection), was approved by the FDA in 2008, providing an alternative for patients who cannot take oral medications.
Emend became an important supportive care product in oncology. The drug addressed a significant unmet need, as delayed CINV (occurring 24 to 120 hours after chemotherapy) was poorly controlled by existing antiemetics. Emend's ability to control both acute and delayed CINV made it a valuable addition to chemotherapy supportive care regimens.
Peak Emend sales reached approximately $550 million annually in the early 2010s. Sales declined after the U.S. patent expired in 2019 and generic aprepitant became available. Generic manufacturers including Sandoz (Novartis), Teva, and others now market aprepitant at significantly lower prices. Merck continues to sell branded Emend, but the product represents a small fraction of the company's overall revenue.
Merck does not separately report Emend revenue in its financial disclosures. The company's revenue is dominated by Keytruda (pembrolizumab), which generated approximately $14.5 billion in 2025 and accounts for the majority of Merck's pharmaceutical sales. Other major Merck products include Gardasil (HPV vaccine), Januvia (diabetes), and Bridion (anesthesia reversal).
What does Merck & Co. own?
Merck & Co. owns a portfolio of pharmaceutical products, vaccines, and animal health products. The company's major brands include Keytruda (oncology immunotherapy), Gardasil (HPV vaccine), Winrevair (pulmonary arterial hypertension), Januvia/Janumet (diabetes), Bridion (anesthesia reversal), Ohtuvayre (COPD), and various other prescription medicines. Merck also operates an animal health division under the Merck Animal Health brand, providing veterinary medicines and vaccines.
Is Merck & Co. publicly traded?
Yes. Merck & Co., Inc. trades on the New York Stock Exchange under ticker symbol MRK. The company has no controlling shareholder, with ownership distributed among institutional investors including Vanguard Group, BlackRock, and State Street.
What is Merck's annual revenue?
In FY2024, Merck reported worldwide sales of $64.2 billion, a 7% increase from FY2023. The Pharmaceutical segment generated approximately $57.4 billion and the Animal Health segment approximately $5.8 billion. Keytruda alone accounted for approximately $29.5 billion in FY2024 sales.
Who is Merck's CEO?
Robert M. Davis has served as Chairman and Chief Executive Officer of Merck & Co. since 2021, succeeding Kenneth Frazier. Davis has led the company's strategy of building a post-Keytruda pipeline through acquisitions and internal research investment.
What is Keytruda and why is it important to Merck?
Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor approved for more than 40 cancer indications. It is the world's best-selling prescription medicine, generating approximately $29.5 billion in FY2024 sales, representing roughly 46% of Merck's total revenue. Keytruda's primary U.S. patent expires in 2028, which will allow biosimilar competition and represents the company's most significant strategic challenge.
What is the difference between Merck & Co. and Merck KGaA?
Merck & Co., Inc. (NYSE: MRK) is an American pharmaceutical company headquartered in Rahway, New Jersey, known as MSD outside the United States and Canada. Merck KGaA is a separate German pharmaceutical and chemical company headquartered in Darmstadt, Germany. The two companies have had no ownership relationship since 1917, when the U.S. government seized German-owned assets and the American entity was incorporated as an independent company.
What is Winrevair?
Winrevair (sotatercept) is a treatment for pulmonary arterial hypertension approved by the FDA in March 2024. It was acquired through Merck's $11.5 billion acquisition of Acceleron Pharma in 2021. Winrevair generated $419 million in FY2024 sales and is expected to become a significant revenue contributor as it addresses a rare disease with limited treatment options.
Emend has maintained a relatively clean safety record since its FDA approval in 2003, with no major recalls or safety controversies.
Drug Interactions: Emend is a moderate inhibitor of CYP3A4, an enzyme involved in the metabolism of many drugs. This can lead to interactions with other medications, including some chemotherapy agents, blood thinners, and certain antidepressants. These interactions are well-characterized and reflected in the prescribing information. Physicians are advised to review patients' medication lists before prescribing Emend.
Hypersensitivity Reactions: Rare cases of hypersensitivity reactions, including anaphylaxis, have been reported with Emend. The prescribing information includes a warning for hypersensitivity reactions, particularly with the IV formulation.
Generic Competition: The primary challenge facing Emend is not a safety controversy but commercial. Since the 2019 patent expiration, generic aprepitant has eroded branded Emend's market share significantly. This is a standard pharmaceutical industry pattern rather than a controversy.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Sandoz Group | USA | 1991 | Mass market | United states | All Genders |
Market Positioning: Emend competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Merck & Co., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Emend which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Emend which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
Band-Aid is privately owned, unlike Emend which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Emend which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Emend which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Konsyl Pharmaceuticals Inc.
Psyllium fiber supplement brand produced by Konsyl Pharmaceuticals, a privately held Maryland company marketing the same psyllium active ingredient as Metamucil since 1934.
Konsyl is privately owned, unlike Emend which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.